Early Postoperative Expansion of Parenchymal High-intensity Areas on T2-weighted Imaging Predicts Delayed @entity2657 Caused by @entity3600 Wafer Implantation in @entity1 with High-grade XXXX .

@entity1 @entity2657 @entity5 @entity4 @entity11 @entity3600
BACKGROUND: @entity3600 (BCNU) wafer (Gliadel(  ) Wafer) implantation after @entity5 resection is an approved treatment for high-grade @entity11 (HGG). These wafers change various characteristics on early postoperative magnetic resonance imaging (ep-MRI) including slight expansion of high-intensity areas on T2-weighted imaging (ep-T2-HIAs) into adjacent parenchyma without restricted diffusivity. We assessed the frequency of the ep-T2-HIAs after BCNU wafer implantation in HGG @entity1 . Moreover, we focused on ep-T2-HIA expansion and its relation to delayed @entity2657 . METHODS: Twenty-five consecutive HGG @entity1 who underwent BCNU wafer implantation were assessed. First, @entity1 were divided into ep-T2-HIA and non-ep-T2-HIA groups, and the incidence of delayed adverse effects was compared between the two groups. Subsequently, the @entity1 were divided into delayed @entity4 and non-delayed @entity4 groups, and pre-, intra-, and postoperative data were compared between the two groups. RESULTS: The ep-T2-HIA expansion and the delayed @entity4 were evident in 9 cases (36%) and 12 cases (48%), respectively. In comparison of the ep-T2-HIA and non-ep-T2-HIA groups, delayed @entity4 was the only delayed adverse effect associated with ep-T2-HIA expansion (P = 0.004). Univariate analysis showed a significantly higher ratio of delayed @entity4 in the subgroups with maximal diameter of removed cavity  <=40 mm (P = 0.047) and the ep-T2-HIA expansion in comparison of the delayed @entity4 and non-delayed @entity4 groups. Multivariate analysis showed that the ep-T2-HIA expansion was the only independent factor associated with delayed @entity4 (P = 0.021). CONCLUSION: In BCNU wafer implantation cases, ep-T2-HIA expansion was a predictive factor for delayed @entity2657 .
